stars 1 stars 2 stars 3

Sironax is a clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory, immunologic, and metabolic diseases. Founded in 2017, the company has built a diverse pipeline of programs by targeting contributors of aging, degeneration, metabolic dysfunction, and inflammation. Sironax is conducting clinical studies with SARM1 inhibitor SIR2501, NAMPT activator SIR4156, and RIPK1 inhibitor SIR9900, in addition to ongoing preclinical research. The company was named to the 2025 Endpoints 11 list of the most promising biotech startups. For more information, visit sironax.com.

Sironax Questions

The Sironax annual revenue was $60.8 million in 2026.

Shefali Agarwal is the President and CEO of Sironax.

31 people are employed at Sironax.

Sironax is based in Waltham, Massachusetts.

Top Sironax Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users